Compare Revvity Inc (RVTY) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Revvity Inc trades at $155.03 (market cap $16.98B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.2 (market cap $560.32M). The key difference: Revvity Inc is far larger — about 30.3× Direxion Daily FTSE China Bull 3x Shares's market cap, and Revvity Inc pays a 0.18% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| RVTY | YINN | |
|---|---|---|
Market Cap | $16.98B | $560.32M |
Volume | 1,456,900 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.36 | $52.69 |
52-Week Low | $82.26 | $21.45 |
Typical Hold Time | 12 Days | 25 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
YINN is trading at $25.09, up 6.49% in the past 24 hours, though technical indicators signal a bearish trend with 17 sell signals versus 2 buy signals. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies and export controls, which may impact the underlying index exposure. Financial ratios remain unavailable for analysis.
The outlook is cautious due to bearish technicals and China-related macroeconomic risks. Opportunities exist if support holds and sentiment improves, but investors face volatility from regulatory developments and weak momentum. Risk management is essential given the conflicting signals between price action and technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
